Edition:
United Kingdom

Pacira Pharmaceuticals Inc (PCRX.OQ)

PCRX.OQ on NASDAQ Stock Exchange Global Select Market

45.15USD
21 Aug 2018
Change (% chg)

$0.15 (+0.33%)
Prev Close
$45.00
Open
$45.00
Day's High
$45.40
Day's Low
$44.60
Volume
156,808
Avg. Vol
152,110
52-wk High
$48.40
52-wk Low
$26.98

Latest Key Developments (Source: Significant Developments)

Aratana Therapeutics Says On July 5, Co, Pacira Pharmaceuticals Entered Amendment, Restatement Of Exclusive License, Development, Commercialization Deal
Monday, 9 Jul 2018 

July 9 (Reuters) - Pacira Pharmaceuticals Inc ::ARATANA THERAPEUTICS - ON JULY 5, CO, PACIRA PHARMACEUTICALS ENTERED AMENDMENT, RESTATEMENT OF EXCLUSIVE LICENSE, DEVELOPMENT, COMMERCIALIZATION DEAL.ARATANA THERAPEUTICS SAYS AMENDED AGREEMENTS PRIMARILY RELATE TO PROVIDING ACCESS AND SUPPLY OF A 10ML VIAL SIZE BY PACIRA TO CO FOR NOCITA(REG).  Full Article

Pacira Announces FDA Approval Of Supplemental New Drug Application For Exparel As A Nerve Block To Produce Regional Analgesia
Friday, 6 Apr 2018 

April 6 (Reuters) - Pacira Pharmaceuticals Inc ::PACIRA ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR EXPAREL® AS A NERVE BLOCK TO PRODUCE REGIONAL ANALGESIA.  Full Article

Pacira Pharmaceuticals Reports Q4 GAAP EPS Of $0.11
Wednesday, 28 Feb 2018 

Feb 28 (Reuters) - Pacira Pharmaceuticals Inc ::PACIRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 NON-GAAP EARNINGS PER SHARE $0.38.Q4 GAAP EARNINGS PER SHARE $0.11.Q4 REVENUE ROSE 8 PERCENT TO $79.1 MILLION.SEES ‍ 2018 EXPAREL NET PRODUCT SALES OF $300 MILLION TO $310 MILLION​.SEES ‍ 2018 NON-GAAP GROSS MARGINS OF 70% TO 72%​.SEES ‍ 2018 NON-GAAP RESEARCH AND DEVELOPMENT EXPENSE OF $50 MILLION TO $60 MILLION​.Q4 EARNINGS PER SHARE VIEW $0.10, REVENUE VIEW $79.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Pacira Says FDA ‍committee ‍Did Not Reach A Unanimous Decision For Exparel As A Nerve Block To Produce Regional Analgesia​
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - Pacira Pharmaceuticals Inc ::PACIRA PHARMACEUTICALS STATEMENT ON FDA ADVISORY COMMITTEE FOR EXPAREL® FOR USE AS A NERVE BLOCK TO PRODUCE REGIONAL ANALGESIA.PACIRA PHARMACEUTICALS INC - ‍PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR COMPLETION OF REVIEW IS APRIL 6, 2018​.PACIRA PHARMACEUTICALS INC - ‍FOUR COMMITTEE MEMBERS VOTED TO RECOMMEND FDA APPROVAL OF EXPAREL SNDA​.PACIRA PHARMACEUTICALS INC -FDA ‍DID NOT REACH A UNANIMOUS DECISION ON EFFICACY AND SAFETY OF USE OF EXPAREL​.PACIRA PHARMACEUTICALS INC - ‍SIX COMMITTEE MEMBERS BELIEVED THAT MORE RESEARCH IS NEEDED TO FURTHER SUPPORT PROPOSED NEW INDICATION FOR EXPAREL SNDA​.PACIRA PHARMACEUTICALS INC -FDA ‍COMMITTEE'S FEEDBACK WILL BE CONSIDERED BY FDA IN ITS REVIEW OF COMPANY'S SNDA SEEKING EXPANSION OF EXPAREL LABEL​.PACIRA - FDA ‍COMMITTEE ‍DID NOT REACH A UNANIMOUS DECISION ON EFFICACY, SAFETY OF USE OF EXPAREL AS A NERVE BLOCK TO PRODUCE REGIONAL ANALGESIA​.  Full Article

Pacira Pharmaceuticals Reports Preliminary 2017 Revenues Of $286.6 Million
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Pacira Pharmaceuticals Inc ::PACIRA PHARMACEUTICALS REPORTS PRELIMINARY 2017 REVENUES OF $286.6 MILLION.Q4 REVENUE $79.1 MILLION VERSUS I/B/E/S VIEW $79.4 MILLION.  Full Article

Pacira Pharmaceuticals reports Q3 non-gaap earnings per share $0.11
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Pacira Pharmaceuticals Inc :Pacira Pharmaceuticals Inc reports third quarter 2017 financial results.Q3 non-gaap earnings per share $0.11.Q3 gaap loss per share $0.19.Q3 revenue $67.3 million versus I/B/E/S view $69.6 million.Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.Pacira Pharmaceuticals Inc - ‍Full-year exparel net product sales guidance revised to $280 to $285 million​.Pacira Pharmaceuticals Inc - ‍Updating its full year 2017 sales guidance and reiterating its remaining financial guidance​.FY2017 revenue view $291.8 million -- Thomson Reuters I/B/E/S.  Full Article

Pacira Pharma to invest up to $25 million in Tela Bio
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Pacira Pharmaceuticals Inc :Committed to invest up to $25 million in Tela Bio, a privately-held surgical reconstruction company​.Under terms of agreement, Pacira will make an initial investment of $15 million​.Under terms of agreement, Pacira is entitled to one seat on Tela Bio board of directors​.Agreement also includes a standstill provision precluding a change of control in Tela Bio for at least 12 months​.  Full Article

Pacira Pharmaceuticals announces FDA acceptance of SNDA
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Pacira Pharmaceuticals Inc :Pacira Pharmaceuticals announces FDA acceptance of SNDA for exparel as a nerve block to produce regional analgesia.Pacira Pharmaceuticals Inc - ‍expected action date by FDA under Prescription Drug User Fee Act (PDUFA) is April 6, 2018​.  Full Article

‍Point72 Asset Management LP reports a 5 pct passive stake in Pacira Pharmaceuticals ​
Tuesday, 22 Aug 2017 

Aug 22 (Reuters) - Pacira Pharmaceuticals Inc :‍Point72 Asset Management LP reports a 5.0 pct passive stake in Pacira Pharmaceuticals Inc as of Aug 21 - SEC filing ​.  Full Article

Healthcor Management L.P.‍ reports a 6.2 pct passive stake in Pacira Pharmaceuticals
Monday, 14 Aug 2017 

Aug 14 (Reuters) - Pacira Pharmaceuticals Inc :Healthcor Management L.P.‍ reports a 6.2 pct passive stake in Pacira Pharmaceuticals, as of Aug 3 - SEC filing ​.  Full Article

BRIEF-Pacira Pharmaceuticals Reports Q1 GAAP Loss Per Share $0.26

* PACIRA PHARMACEUTICALS, INC. REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS